Radiopharm Theranostics Files 6-K Report
Ticker: RDPTF · Form: 6-K · Filed: Sep 15, 2025 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Sep 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, foreign-private-issuer
TL;DR
Radiopharm Theranostics (RPTX) filed a routine 6-K, confirming its foreign private issuer status.
AI Summary
Radiopharm Theranostics Limited, a pharmaceutical preparations company, filed a Form 6-K on September 15, 2025. The filing is a report of a foreign private issuer for the month of September 2025. The company's principal executive office is located in Carlton South, Victoria, Australia.
Why It Matters
This filing indicates ongoing reporting requirements for Radiopharm Theranostics as a foreign private issuer, providing transparency to investors about its regulatory status.
Risk Assessment
Risk Level: low — This filing is a standard regulatory report and does not contain new material financial or operational information that would inherently increase risk.
Key Numbers
- 001-41621 — SEC File Number (Identifies the company's filing with the SEC.)
Key Players & Entities
- Radiopharm Theranostics Limited (company) — Registrant
- 001-41621 (company) — SEC File Number
- September 2025 (date) — Reporting Period
- Carlton South, Victoria, Australia (location) — Principal Executive Office
FAQ
What type of filing is this Form 6-K?
This Form 6-K is a Report of Foreign Private Issuer.
What is the reporting period for this Form 6-K?
The reporting period is for the month of September 2025.
Where is Radiopharm Theranostics Limited's principal executive office located?
The principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia.
Does Radiopharm Theranostics file annual reports under Form 20-F?
Yes, the registrant indicates it files annual reports under cover of Form 20-F.
Is Radiopharm Theranostics furnishing information under Rule 12g3-2(b)?
No, the registrant indicated 'No' for furnishing information under Rule 12g3-2(b).
Filing Stats: 318 words · 1 min read · ~1 pages · Grade level 19.2 · Accepted 2025-09-15 08:26:32
Filing Documents
- ea0257333-6k_radio.htm (6-K) — 18KB
- ea025733301ex99-1_radio.htm (EX-99.1) — 20KB
- ex99-1_001.jpg (GRAPHIC) — 52KB
- 0001213900-25-087432.txt ( ) — 111KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of September 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published one announcement (the “Public Notice”) to the Australian Securities Exchange on September 15, 2025 titled: - “Pivalate (Brain Mets) key opinion leader webinar” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Pivalate (Brain Mets) key opinion leader webinar 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: September 15, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3